Description
Chronic inflammation and enhanced production of ROS have been considered risk factors for developing CVDs. Some oxidative stress and inflammation markers are enhanced in CVDs and harbour prognostic implications. For all these reasons, antioxidants or anti-inflammatory drugs may represent promising therapies. Nevertheless, only a few clinical trials targeting ROS and inflammatory mediators demonstrated beneficial effects of such targeting due to the pleiotropic effect of antioxidant and anti-inflammatory drugs. This highlights the complexity of immune and redox systems and indicates that other approaches are essential to assess value of therapeutic modulation of ROS and inflammation in CVDs.This research article collection aims to provide insight into the biology and pathophysiology of ROS production, immune mediators and their mutual interaction as factors leading to the development of CVDs. Understanding novel cellular and molecular pathways affected by inflammatory mediators and ROS is essential for understanding the pathology related to CVDs. Moreover, it will enable future discovery of novel integrative therapeutic approaches targeting CVDs.
| Period | 2022 → … |
|---|---|
| ISSN | 2297-055X |